Jonathan Ole Rayner

US Patent:

7425337, Sep 16, 2008

Filed:

Mar 16, 2006

Appl. No.:

11/376901

Inventors:

Jonathan F. Smith - Cary NC, US
Kurt I. Kamrud - Apex NC, US
Jonathan O. Rayner - Apex NC, US
Sergey A. Dryga - Chapel Hill NC, US
Ian J. Caley - Durham NC, US

Assignee:

AlphaVax, Inc. - Research Triangle Park NC

International Classification:

A61K 39/12
C12N 15/64
C12N 5/02

US Classification:

4242181, 435325, 435 9142

Abstract:

The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.

US Patent:

20030119182, Jun 26, 2003

Filed:

Sep 6, 2002

Appl. No.:

10/237302

Inventors:

Jonathan Smith - Cary NC, US
Kurt Kamrud - Apex NC, US
Jonathan Rayner - Apex NC, US
Sergey Dryga - Chapel Hill NC, US
Ian Caley - Durham NC, US

International Classification:

C12Q001/70
C12P021/06
C12P019/34
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

US Classification:

435/320100, 435/069100, 435/091100, 435/005000

Abstract:

The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication-competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.